INSM Overview
Upcoming Projects (INSM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (INSM)
-
Investigating the topline results from the Phase 3 ASPEN clinical trial of Brensocatib in patients with bronchiectasis.
Ticker: INSM
Executed On: Jun 04, 2024 at 11:00 AM EDT -
Discussing DPP1 inhibition and its potential in bronchiectasis
Ticker: INSM
Executed On: May 09, 2024 at 04:00 PM EDT -
A Second Look: Exploring Potential of Brensocatib in Bronchiectasis - A Deep Dive into Insmed's ASPEN Study.
Ticker: INSM
Executed On: Apr 04, 2024 at 03:00 PM EDT -
Exploring the Potential of Brensocatib in Bronchiectasis: A Deep Dive into Insmed's ASPEN Study
Ticker: INSM
Executed On: Apr 01, 2024 at 09:30 AM EDT
Expired Projects (INSM)
Upcoming & Overdue Catalysts (INSM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (INSM)
-
Top-Line Results Revealed from Insmed's (INSM) Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
Ticker: INSM
Occurred on: Feb 03, 2020 -
Insmed (INSM) Expects to Begin Phase 2 Dose-Ranging Study in 2017 Evaluating AstraZeneca's (AZN) AZD7986 in Non-Cystic Fibrosis Bronchiectasis
Tickers: INSM, AZN
Occurred on: Jul 17, 2017 -
Insmed Announces Withdrawal of Marketing Authorization Application for ARIKAYCE in Europe
Ticker: INSM
Occurred on: Jun 08, 2016
Strategic Initiatives (INSM)
-
Insmed (INSM) and AstraZeneca (AZN) Announce Worldwide License Agreement Giving INSM Global Exclusive Rights to Develop AZD7986 in Non-Cystic Fibrosis Bronchiectasis
Tickers: INSM, AZN
Announcement Date: Oct 05, 2016
